我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

关于铋剂与质子泵抑制剂联用的思考(PDF)

《医学争鸣》[ISSN:1000-2790/CN:61-1060/R]

期数:
2020年01期
页码:
53-57
栏目:
学术探讨
出版日期:
2020-02-29

文章信息/Info

Title:
Combination of bismuth and proton pump inhibitor in Helicobacter pylori eradication therapy
作者:
唐 莉蔡燕峰杨 勤金小晶
( 南京中医药大学附属南京中医院脾胃病科,江苏 南京 210001)
Author(s):
TANG Li CAI Yanfeng YANG Qin JIN Xiaojin
Department of Spleen-Stomach Diseases, Nanjing Hospital of Traditional Chinese Medicine, Nanjing University of Traditional Chinese Medicine, Nanjing 210001, China
关键词:
铋剂幽门螺杆菌质子泵抑制剂
Keywords:
bismuth Helicobacter pylori proton pump inhibitor
分类号:
R573
DOI:
10.13276/j.issn.1674-8913.2020.01.014
文献标识码:
A
摘要:
我国幽门螺杆菌(H. pylori)感染共识报告推荐铋剂四联疗法作为一线根除方案,但是 铋剂与质子泵抑制剂联用是否安全合理、有无违规、如何联用仍有许多疑惑。现通过整理分析铋剂 与质子泵抑制剂联用的相关文献发现,抑制胃酸可能影响铋剂药效,质子泵抑制剂可增加铋剂吸收 与蓄积,可致血铋浓度升高,脏器中铋蓄积量增加。此外,各国指南或共识中铋剂四联疗法的证据 级别均较低,缺乏高质量随机对照研究或药效/药代动力学研究的支持。不同国家或地区对于铋剂四 联方案推荐级别不同,并非均作为一线根除方案,欧美日等一些国家尚未批准常规使用铋剂治疗H. pylori相关的胃病,并且铋剂与质子泵抑制剂联用有违铋剂的药品说明书。本文就铋剂与质子泵抑制 剂联用的若干问题作一初步探讨,旨在引起同道对H. pylori根除方案中联合用药的合理性、安全性的 进一步思考和研究。
Abstract:
The Chinese consensus report on helicobacter pylori infection recommended bismuth quadruple therapy as the first-line eradication therapy. However, there are many doubts regarding whether the combination of bismuth and proton pump inhibitor is safe and reasonable, and how to use it probably. After searching for the related literatures, we found that the inhibition of gastric acid might affect the efficacy of bismuth. Proton pump inhibitors can increase bismuth absorption and accumulation, lead to the increase of bismuth concentration in blood and bismuth accumulation in viscera. In addition, the level of evidence for bismuth quadruple therapy in national guidelines or consensus is relatively low due to a lack of the support from high-quality randomized controlled trials or pharmacodynamics/pharmacokinetic studies. Different countries or regions have different recommendation levels for bismuth quadruple therapy, which is not always as first-line eradication therapy. Some countries, such as Europe, America and Japan, have not allowed the routine use of bismuth for the treatment of Helicobacter pylori-related gastric diseases. And the bismuth combined with proton pump inhibitor goes against the instructions of the bismuth. In this paper, some questions about the combination of bismuth and proton-pump inhibitors are discussed, in order to spur further consideration and research on the rationality and safety of the drug combination in the Helicobacter pylori eradication therapy.

参考文献/References

[1] Marshall BJ, Armstrong JA, Francis GJ, et al. Antibacterial action of bismuth in relation to Campylobacter pyloridis colonization and gastritis[J]. Digestion, 1987, 37 (Suppl 2):16-30.
[2] Goodwin CS, Armstrong JA, Wilson DH. Differences between in vitro and in vivo sensitivity of Campylobacter pylori to antimicrobials[J]. Campylobacter Pylori, 1989: 29-36.
[3] Li W, Jin L, Zhu N, et al. Structure of colloidal bismuth subcitrate (CBS) in dilute HCl: unique assembly of bismuth citrate dinuclear units ([Bi(cit)(2)Bi](2-))[J]. J Am Chem Soc, 2003, 125(41):12408-12409.
[4] Keogan DM, Griffith DM. Current and potential applications of bismuth-based drugs[J]. Molecules, 2014, 19(9):15258-15297.
[5] 牛春燕, 罗金燕, 朱有玲, 等. 雷贝拉唑首次单剂量口服 的抑酸效应对比研究[J]. 胃肠病学和肝病学杂志, 2003, 12(02):183-185.
[6] Figura N, Crabtree JE, Dattilo M. In-vitro activity of lansoprazole against Helicobacter pylori[J]. J Antimicrobial Chemother, 1997, 39(5):585-590.
[7] Treiber G, Walker S, Klotz U. Omeprazole-induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate[J]. Clin Pharmacol Ther, 1994, 55(5):486-491.
[8] Spénard J, Aumais C, Massicotte J, et al. Influence of omeprazole on bioavailability of bismuth following administration of a triple capsule of bismuth biskalcitrate, metronidazole, and tetracycline[J]. J Clin Pharmacol, 2004,44(6):640-645.
[9] 张澍田, 张松华, 于中麟, 等. 单一和四联疗法根除幽门 螺杆菌对果胶铋吸收和代谢的影响[J]. 中华医学杂志, 2002, 82(13):11-13.
[10] Slikkerveer A, Wolff FA. Pharmacokinetics and toxicity of bismuth compounds[J]. Med Toxicol Adverse Drug Exp, 1989, 4(5):303-323.
[11] 张 莉, 张澍田, 于中麟, 等. 根除幽门螺杆菌治疗对 胶体次枸橼酸铋代谢的影响[J]. 中华内科杂志, 2005, 44(04):272-275.
[12] Slikkerveer A, Helmich RB, de Wolff FA. Analysis for bismuth in tissue by electrothermal atomic absorption spectrometry[J]. Clin Chem, 1993, 39(5):800-803.
[13] 杨秀疆, 陈士葆. 胶态次枸橼酸铋的不良反应[J]. 新药与 临床, 1992 (03):178-180.
[14] Liu Y, Shen C, Zhang X, et al. Exposure and nephrotoxicity concern of bismuth with the occurrence of autophagy[J]. Toxicol Ind Health, 2018, 34(3):188-199.
[15] Cengiz N, Uslu Y, Gök F, et al. Acute renal failure after overdose of colloidal bismuth subcitrate[J]. Pediatr Nephrol, 2005, 20(9):1355-1358.
[16] Erden A, Karahan S, Bulut K, et al. A case of bismuth intoxication with irreversible renal damage[J]. Int J Nephrol Renovasc Dis, 2013,11(6):241-243.
[17] 张 莉, 张澍田, 于中麟, 等. 根除幽门螺杆菌的抑酸治 疗促进铋剂在肾脏中蓄积的形态学观察[J]. 中华医学杂 志, 2005, 85(4):45-49.
[18] Gane E, Sutton MM, Pybus J, et al. Hepatic and cerebrospinal fluid accumulation of aluminum and bismuth in volunteers taking short course anti-ulcer therapy[J]. J Gastroenterol Hepatol, 1996, 11(10):911-915.
[19] Benet LZ. Safety and pharmacokinetics: colloidal bismuth subcitrate[J]. Scand J Gastroenterol Suppl, 1991, 185:29-35.
[20] Malfertheiner P, Megraud F, O’Morain CA, et al. Management of Helicobacter pylori infection—the Maastricht V/Florence Consensus Report[J]. Gut, 2017, 66(1):6-30.
[21] Chey WD, Leontiadis GI, Howden CW, et al. ACG clinical guideline: treatment of Helicobacter pylori infection [J]. Am J Gastroenterol, 2017, 112(2):212-239.
[22] 刘文忠, 谢 勇, 陆 红, 等. 第五次全国幽门螺杆菌感 染处理共识报告[J]. 胃肠病学, 2017, 22(6):346-360.
[23] Kim SG, Jung HK, Lee HL, et al. Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition[J]. J Gastroenterol Hepatol, 2014, 29(7):1371-1386.
[24] Zagari RM, Romano M, Ojetti V, et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015[J]. Dig Liver Dis, 2015, 47(11):903-912.
[25] Malfertheiner P, Bazzoli F, Delchier JC, et al. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial [J]. Lancet, 2011, 377(9769):905-913.
[26] Smith S, Boyle B, Brennan D, et al. The Irish Helicobacter pylori Working Group consensus for the diagnosis and treatment of H. pylori infection in adult patients in Ireland[J]. Eur J Gastroenterol Hepatol, 2017, 29(5):552- 559.
[27] Asaka M, Kato M, Takahashi S, et al. Guidelines for the management of Helicobacter pylori infection in Japan: 2009 revised edition[J]. Helicobacter, 2010,15(1):1-20.
[28] Satoh K, Yoshino J, Akamatsu T, et al. Evidence-based clinical practice guidelines for peptic ulcer disease 2015[J]. J Gastroenterol, 2016, 51(3):177-194.
[29] 王珏磊, 刘星宇, 聂 燕, 等. 对铋剂在临床应用利弊的 思考[J]. 中华内科杂志, 2012, 51(12):932-934.
[30] Graham DY, Lee SY. How to effectively use bismuth quadruple therapy: the good, the bad, and the ugly[J]. Gastroenterol Clin North Am, 2015, 44(3):537-563.
[31] Songür Y, Senol A, Balkarli A, et al. Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment[J]. Am J Med Sci, 2009, 338(1):50-53.
[32] Li L, Meng F, Zhu S, et al. Efficacy and safety of Wei Bi Mei, a Chinese herb compound, as an alternative to bismuth for eradication of Helicobacter pylori[J]. Evid Based Complement Alternat Med, 2018: 4320219.

备注/Memo

备注/Memo:
基金项目:南京市科技发展计划项目(201605037)
通信作者:金小晶。Tel:13305190720,E-mail:jinxiaojing7@163.com
作者简介:唐 莉。硕士,住院医师。研究方向:中西医消化系统疾病的理论及临床研究。Tel:17327007269,E-mail:tang-tl@hotmail.com
更新日期/Last Update: 2020-03-09